Skip to content

FGF23 as a Marker of Acute Kidney Injury

Fibroblast Growth Factor-23 as a Marker of Acute Kidney Injury After Partial Nephrectomy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04693962
Enrollment
40
Registered
2021-01-05
Start date
2017-04-01
Completion date
2021-12-01
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Kidney Ischemia

Keywords

Acute kidney injury, Creatinine, Fibroblast Growth Factor-23

Brief summary

A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection. Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose is based on the increase in plasma creatinine concentration and a decrease in urine output. However, both plasma creatinine concentration and diuresis are useful for the diagnose, but not in the detection of the risk patients. Therefore, there is considerable interest to find a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence, we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect patients in risk to develop postoperative AKI after a PN. We will conduct an observational and prospective study in three different groups of patients: PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC; and Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with physical injury. In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23 were measure. Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where patients are exposed to a controlled ischemic injury.

Interventions

DIAGNOSTIC_TESTPlasmatic Fibroblast Growth Factor-23 by means of ELISA

Plasma levels of FGF-23 will be measured by ELISA

Sponsors

University of Chile
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* American Society of Anesthesiology physical status (ASA) I or II. * Normal preoperative plasma creatinine level * Baseline estimated glomerular filtration rate (eGFR) \> 60 ml/min per 1.73 m2.

Exclusion criteria

* History of chronic kidney disease * Anemia * Alterations in the parathormone or vitamin D axis * Pregnant women * Subjects with concomitant use of nephrotoxic drugs.

Design outcomes

Primary

MeasureTime frameDescription
Acute Kidney Injury72 hoursPatients that develop postoperative acute kidney injury

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026